- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04647786
Safe and Effective Above Cuff Tracheostomy Ventilation (SEACtV)
Safe and Effective Above Cuff Tracheostomy Ventilation - a Device Development Study
A Phase I study of an 'in-house' developed, novel, Class I, prototype medical device to facilitate vocalisation in participants with cuff-inflated tracheostomy tubes.
Primary objective: To design and develop a device to deliver Above Cuff Vocalisation (ACV) that is safe, well tolerated and effective at producing a voice in tracheostomised patients in the Intensive Care Unit (ICU).
Secondary objective: To evaluate whether more effective delivery of ACV has a significant impact on laryngeal function and recovery following new tracheostomy in ICU patients.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A tracheostomy is an artificial airway inserted into the trachea (windpipe) through the front of the neck, usually required for prolonged artificial ventilation in the critically ill. Between 10-15% of the 250,000 patients admitted annually to UK Intensive Care Units (ICUs) require temporary tracheostomy, with an additional 5,000 tracheostomies performed during surgery. The tubes have a cuff/balloon which seals the trachea when inflated, allowing lung ventilation. The flow of gas into and out of the patient's lungs does not flow through the upper airways (nose and mouth), bypassing the larynx (voice box) and preventing speech. Our research found the biggest problem with tracheostomies from the patient's perspective is losing the ability to speak. If the muscles of the larynx and throat are not used, they quickly become weak, meaning that coughing, swallowing and talking can take longer to recover. These problems cause anger, frustration, fear and low mood and lead to significantly longer hospital stays, impacting ICU and hospital bed availability.
Patients with a weak cough or swallow cannot clear secretions from the throat, which may enter the lungs (aspiration). The inflated cuff reduces aspiration and most ICU-specific tubes have an extra suction-port for secretion removal. However, additional gas can be directed via the suction-port, through the vocal cords and out via the upper airways, allowing vocalisation. The MHRA confirmed these tubes can be used for 'above cuff voicing' (ACV) in line with their CE marking.
Our proposed research advances healthcare technologies by developing a new clinically validated prototype medical device with the potential to significantly increase patient benefit for a defined and expanding area of clinical need. Our collaborative project combines our clinical experience and understanding of the needs of tracheostomy patients and their families with the design and engineering excellence of our University and SME partners. Our team is supported by individual and institutional research expertise and together with our patient partners, we can deliver an advanced prototype device with a clear pathway towards adoption and commercialisation, attractive to follow-on funders and investors.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Manchester, United Kingdom, M23 9LT
- Recruiting
- Manchester University NHS Foundation Trust
-
Contact:
- Brendan McGrath
- Phone Number: 01612916420
- Email: brendan.mcgrath@manchester.ac.uk
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Inclusion criteria (patient):
- Provision of informed consent prior to any study specific procedures
- cuff-inflated tracheosotmy tube in situ for >48 hours
- managed on an Intensive Care Unit at MFT
- Male and females
- Aged 18-100; patient is alert and attempting to communicate (and thus able to participate in the consent process).
Inclusion criteria (staff):
- Provision of informed consent
- bedside clinical staff (medical, nursing, allied healthcare professional) who manage the patient during routine clinical duties whilst ACV is in progress.
Exclusion Criteria:
Exclusion criteria (patient): Participants must not enter the study if any of the following exclusion criteria are fulfilled:
- Patient refusal
- ACV is not indicated in the opinion of the parent clinical team
- Patient has (or is suspected to have) an altered and therefore potentially obstructed upper airway
- Patient has (or is suspected to have) an active and currently infectious high-consequence respiratory infection that could be transmitted by aerosolisation (eg COVID-19)
- Clinical condition has progressed so that the patient is tolerating cuff deflation and a speaking valve well and is able to voice effectively (ie without ACV: this negates the requirement for an ACV trial); Contraindications to FEES (adapted from RCSLT FEES policy) o Base of skull / facial fracture; Severe/life threatening epistaxis within the last 6 weeks; Trauma to nasal cavity secondary to surgery or injury within the last 6 weeks; Sino-nasal and anterior skull base tumours / surgery; Nasopharyngeal stenosis; Craniofacial anomalies; Hereditary Haemorrhagic telangiectasia
Exclusion criteria (staff): Refusal to participate.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Humidified and Augmented gas flows
|
A prototype device that delivers a controlled flow of gas to the upper airways via the subglottic suction port of an established tracheostomy tube.
Gas flow may be timed, warmed and/or humidified.
|
Experimental: Humidified but not Augmented gas flows
|
A prototype device that delivers a controlled flow of gas to the upper airways via the subglottic suction port of an established tracheostomy tube.
Gas flow may be timed, warmed and/or humidified.
|
Experimental: Not Humidified but Augmented gas flows
|
A prototype device that delivers a controlled flow of gas to the upper airways via the subglottic suction port of an established tracheostomy tube.
Gas flow may be timed, warmed and/or humidified.
|
No Intervention: Neither humidified nor augmented gas flows
|
|
Experimental: Use of finalised device (SEA CtV) in final phase
|
A prototype device that delivers a controlled flow of gas to the upper airways via the subglottic suction port of an established tracheostomy tube.
Gas flow may be timed, warmed and/or humidified.
|
No Intervention: Standard care (no SEA CtV)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effectiveness of vocalisation (Patient-reported voice VAS)
Time Frame: Daily for up to 7 days
|
To assess the effectiveness of the SEA CtV prototype device in producing a voice for cuff-inflated tracheostomy patients.
|
Daily for up to 7 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Voice rating
Time Frame: Daily for up to 7 days
|
(Objective scales FCS, NoWS, TOMS, GRBAS, recordings for volume and intelligibility); Cough count; Swallow count; e-Stim (threshold/max sensetivities); FEES (Laryngeal function scales Pen-Asp, SSRS, APS)
|
Daily for up to 7 days
|
Adverse events record
Time Frame: Daily for up to 7 days
|
Adverse events record (tracheosotmy tube displacement, surgical emphysema), adverse events log, setup safety tests (does the device stop appropriately)
|
Daily for up to 7 days
|
Patient reported subjective tolerability
Time Frame: Daily for up to 7 days
|
Patient-reported subjective tolerability VAS; Staff-reported objective tolerability VAS; Patient-reported problems; ACV device use
|
Daily for up to 7 days
|
Time to first oral intake
Time Frame: Daily for up to 7 days
|
Time to oral intake; Functional Swallowing Outcome; vocalisation; cuff deflation for >2 hours; ETT days; Trachy days; ICU days; hospital days; CCMDS organ supoort data
|
Daily for up to 7 days
|
Collaborators and Investigators
Collaborators
Publications and helpful links
General Publications
- McGrath BA, Wallace S, Wilson M, Nicholson L, Felton T, Bowyer C, Bentley AM. Safety and feasibility of above cuff vocalisation for ventilator-dependant patients with tracheostomies. J Intensive Care Soc. 2019 Feb;20(1):59-65. doi: 10.1177/1751143718767055. Epub 2018 Mar 28.
- Zaga CJ, Pandian V, Brodsky MB, Wallace S, Cameron TS, Chao C, Orloff LA, Atkins NE, McGrath BA, Lazarus CL, Vogel AP, Brenner MJ. Speech-Language Pathology Guidance for Tracheostomy During the COVID-19 Pandemic: An International Multidisciplinary Perspective. Am J Speech Lang Pathol. 2020 Aug 4;29(3):1320-1334. doi: 10.1044/2020_AJSLP-20-00089. Epub 2020 Jun 11.
- McGrath B, Lynch J, Wilson M, Nicholson L, Wallace S. Above cuff vocalisation: A novel technique for communication in the ventilator-dependent tracheostomy patient. J Intensive Care Soc. 2016 Feb;17(1):19-26. doi: 10.1177/1751143715607549. Epub 2015 Oct 5.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- B00990
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tracheostomy
-
University of MilanASST Santi Paolo e Carlo; Dejan Radovanovic; Marina Gatti; Michele Mondoni; Stefano... and other collaboratorsNot yet recruiting
-
Centre Hospitalier Universitaire, AmiensCompletedTracheostomy Hemorrhage | Tracheostomy Complications | Other Tracheostomy ComplicationsFrance
-
Diskapi Yildirim Beyazit Education and Research...CompletedTracheostomy Complication | Percutaneous Tracheostomy | High-frequency Jet VentilationTurkey
-
Universitatea de Medicina si Farmacie Iuliu HatieganuRecruitingTracheostomy Complication | Tracheostomy Infection | Tracheostomy HemorrhageRomania
-
Aksaray UniversityNot yet recruitingTracheostomy Complication | Percutaneous Tracheostomy | Airway Trauma | Tracheostomy HemorrhageTurkey
-
Johns Hopkins UniversityNot yet recruitingTracheostomyUnited States
-
Capital Medical UniversityCompleted
-
Atos Medical ABCompleted
-
University of AlbertaAlberta Innovates Health SolutionsNot yet recruiting
Clinical Trials on Prototype medical device (SEA CtV)
-
Cryonove PharmaCEISO; Dermatech; INNOVSOLUTIONCompleted
-
University of California, San FranciscoMount Zion Health FundNot yet recruitingHead and Neck Cancer | TrismusUnited States
-
Cryonove PharmaCEISO; Dermatech; INNOVSOLUTIONCompleted
-
National University Hospital, SingaporeNational University of SingaporeRecruiting
-
University of Kansas Medical CenterContinuum Educational TechnologiesNot yet recruiting
-
University of ChicagoCompletedShock | Acute Respiratory Distress Syndrome | Ventilatory Failure | Cardiogenic Pulmonary EdemaUnited States
-
University of CalgaryAxem Neurotechnology Inc.Not yet recruiting
-
NeuroEnabling Technologies, Inc.University of California, Los Angeles; California Institute of TechnologyCompletedParalysis | Spinal Cord InjuryUnited States
-
NeuroEnabling Technologies, Inc.University of California, Los Angeles; California Institute of TechnologyCompleted